The Company has been coordinating for several months on its participation in this study with senior administrators. The study will test subjects under the influence of marijuana alongside several conventional drug screening methods (blood, oral fluid etc.), in conjunction with the use of Cannabix’s proprietary breath capture and marijuana detection equipment. Further, details of the study will be available in due course when disclosure approvals are granted to the Company.

This kind of study underway in southern United States will provide an important launch point for Cannabix devices in terms of a law enforcement and toxicology audience. Cannabix is using its marijuana breathalyzer technology to detect ∆9-tetrahydrocannabinol (“THC”) – the psychoactive component of marijuana that causes impairment, in breath. Breath testing for THC would allow law enforcement to quickly and practically identify recent marijuana use that aligns with the timing window of impairment, unlike other technologies such as saliva or urine.